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In 2012, the European Centre for Disease Prevention 
and Control (ECDC) launched the ‘European survey 
of carbapenemase-producing Enterobacteriaceae 
(EuSCAPE)’ project to gain insights into the occur-
rence and epidemiology of carbapenemase-producing 
Enterobacteriaceae (CPE), to increase the awareness of 
the spread of CPE, and to build and enhance the labo-
ratory capacity for diagnosis and surveillance of CPE in 
Europe. Data collected through a post-EuSCAPE feed-
back questionnaire in May 2015 documented improve-
ment compared with 2013 in capacity and ability to 
detect CPE and identify the different carbapenemases 
genes in the 38 participating countries, thus contrib-
uting to their awareness of and knowledge about the 
spread of CPE. Over the last two years, the epidemio-
logical situation of CPE worsened, in particular with 
the rapid spread of carbapenem-hydrolysing oxacil-
linase-48 (OXA-48)- and New Delhi metallo-beta-
lactamase (NDM)-producing Enterobacteriaceae. In 
2015, 13/38 countries reported inter-regional spread 
of or an endemic situation for CPE, compared with 
6/38 in 2013. Only three countries replied that they 
had not identified one single case of CPE. The ongo-
ing spread of CPE represents an increasing threat to 
patient safety in European hospitals, and a majority of 
countries reacted by establishing national CPE surveil-
lances systems and issuing guidance on control meas-
ures for health professionals. However, 14 countries 
still lacked specific national guidelines for prevention 
and control of CPE in mid-2015.
Introduction
The global rise of carbapenemase-producing 
Enterobacteriaceae (CPE) is alarming and represents 
an increasing threat to healthcare delivery and 
patient safety in Europe and beyond.
In 2012, the European Centre for Disease Prevention 
and Control (ECDC) launched the ’European survey 
of carbapenemase-producing Enterobacteriaceae 
(EuSCAPE)’ project to improve the understanding of 
the occurrence and epidemiology of CPE, to increase 
awareness of the spread of CPE and to build laboratory 
capacity for diagnosis and surveillance in Europe.
In February 2013, a self-assessment questionnaire 
was sent to one national expert (NE) from each of the 
EuSCAPE participating countries (i.e. 28 European 
Union (EU) Member States, Iceland, Norway, the 
seven EU enlargement countries (Albania, Bosnia 
and Herzegovina, Kosovo*, Montenegro, the former 
Yugoslav Republic of Macedonia, Serbia and Turkey) 
and Israel, to gather information on the current aware-
ness of and knowledge about the spread of CPE, the 
public health responses and the available national 
guidelines on detection, surveillance, prevention 
and control, as well as on the capacity for laboratory 
diagnosis and surveillance. NEs were chosen based 
on their national and international laboratory and/
or epidemiological experience in CPE among experts 
from national reference or expert laboratories, from 
the European Antimicrobial Resistance Surveillance 
Network (EARS-Net), and from the ECDC Coordinating 
Competent Bodies (National Focal Points for antimi-
crobial resistance and National Focal Points for micro-
biology) and ECDC National Correspondents for EU 
enlargement countries. The answers collected from the 
NEs showed that the epidemiological situation for CPE 
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had worsened since 2010 and CPE continued to spread 
in European hospitals [1-3]. Answers also indicated that 
the knowledge and awareness of the spread of CPE and 
the laboratory capacity for diagnosis and surveillance 
were heterogeneous among countries [1,2]. These find-
ings highlighted the urgent need for a coordinated 
European effort towards early diagnosis, active surveil-
lance and guidance on infection control measures [1,2].
In September and October 2013, the EuSCAPE project 
supported laboratory capacity building for diagnosis 
and surveillance by hosting a ‘train-the-trainer’ work-
shop at the European level for national laboratory 
experts on the identification and confirmation of CPE, 
and by carrying out an external quality assessment 
(EQA) of national reference/expert laboratories. The 
workshop and the EQA aimed at ensuring performance 
quality, consistency and comparability of data between 
participating countries and laboratories. Between 
November 2013 and April 2014, 36 European coun-
tries participated in the first European-wide structured 
survey of CPE (data not shown). The participating ref-
erence/expert laboratories were asked to collect CPE 
isolates of Klebsiella pneumoniae and Escherichia coli 
together with clinical data on these CPE-related infec-
tions to gain an understanding on the prevalence and 
epidemiology of CPE, as well as the risk factors associ-
ated with CPE infections in Europe.
In March 2015, after the completion of the EuSCAPE 
project, a post-EuSCAPE feedback questionnaire 
was sent to the participating countries to document 
whether (i) knowledge and awareness regarding the 
occurrence and spread of CPE had increased, and (ii) 
national capacity for containment of CPE had changed 
in terms of surveillance, laboratory reference services, 
and availability of guidance on infection prevention 
and control measures for these bacteria, since February 
2013.
In this report, we present the analysis of the NEs’ 
answers on behalf of their countries to the post-EuS-
CAPE feedback questionnaire and provide summaries 
of the current epidemiological situation of the spread 
of CPE in each country.
Methods
The post-EuSCAPE feedback questionnaire was derived 
from the self-assessment questionnaire issued in 
February 2013 [1,2]. The questionnaire was divided in 
five sections. The first two sections explored aware-
ness and knowledge about the occurrence of CPE in 
each country and collected information on the current 
national capacity for containment of CPE. The third and 
fourth sections collected the participants’ feedback on 
the EuSCAPE activities, e.g. laboratory capacity build-
ing workshop, EQA exercise and on the impact of the 
EuSCAPE project on collaborations and networking 
capacity, respectively. The fifth section investigated 
Figure 1
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desired areas for future ECDC activities on carbapenem-
resistant Gram-negative bacteria. The questionnaire 
was sent to the same NEs who participated in a similar 
survey in February 2013, with the exception of France 
and the Netherlands. They were invited to coordinate 
their replies with colleagues in their countries i.e. the 
ECDC National Focal Points for antimicrobial resist-
ance and the ECDC National Correspondents for EU 
enlargement countries) to reflect the national situation 
and to complete the questionnaire online between 3 
March and 30 April 2015 (questionnaire available upon 
request from the corresponding author). They were 
also asked to provide a description of the emergence 
and spread of CPE in their country beyond K. pneumo-
niae and E. coli isolates collected during the EuSCAPE 
structured survey. The answers were based on their 
knowledge of national clinical and microbiological data 
and/or their personal judgement. When necessary, the 
respondents were contacted for clarification, and cor-
rections were made accordingly. The latest data from 
Figure 2
Geographic distribution of carbapenemase-producing Enterobacteriaceae by resistance mechanism, based on self-assessment 
by national experts, 38 European countries, May 201
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EARS-Net provided an additional source of information 
on the percentage of carbapenem resistance in inva-
sive isolates, in the EU/ European Economic Area (EEA) 
Member States.
For the presentation, countries were arbitrarily grouped 
in geographic entities independently of the epidemio-
logical stages of CPE spread, geopolitical or economic 
considerations.
Using the same epidemiological staging system as in 
2010 and 2013 (Table 1), all participating countries 
self-assessed their epidemiological situation of CPE, 
thereby documenting the progression of CPE within 
countries and dissemination in Europe between 2013 
and 2015. All countries provided a self-assessment of 
the current national situation.
Results
Overall occurrence of carbapenemase-
producing Enterobacteriaceae
Three countries reported not having identified one 
single case of CPE, whereas 13 reported regional and 
inter-regional spread, and four reported an endemic 
situation. Nine countries reported sporadic occur-
rence, five reported single hospital outbreak and four 
reported sporadic hospital outbreaks (Figure 1, Table 
2).
Table 2 documents the epidemiological stages and dis-
semination for CPE within countries in the years 2010, 
2013 and 2015 and indicates the changes in status 
between surveys in 2013 and 2015.
Occurrence of carbapenemase-producing 
Enterobacteriaceae by type of carbapenemase
All countries were able to rate the occurrence and 
spread of CPE by type of carbapenemase. As of May 
2015, K. pneumoniae carbapenemase (KPC)-producing 
Enterobacteriaceae still had the widest dissemination 
in Europe, but carbapenem-hydrolysing oxacillinase-48 
(OXA-48)-producing Enterobacteriaceae had almost 
reached the same spread, a change compared with 
February 2013, with eight countries reporting regional 
or inter-regional spread and another two countries 
reporting an endemic situation (Figure 2). The distribu-
tion of KPC- and OXA-48-producing Enterobacteriaceae 
varies and does not necessarily overlap, for exam-
ple, Greece seeing predominantly KPC-producing 
Enterobacteriaceae and rarely OXA-48-producing 
Enterobacteriaceae, and Malta seeing almost exclu-
sively OXA-48-producing Enterobacteriaceae.
The European epidemiology for CPE also changed 
between 2013 and 2015 for New Delhi metallo-beta-lac-
tamase (NDM)-producing Enterobacteriaceae; five coun-
tries reported sporadic hospital outbreaks, and seven 
countries regional or inter-regional spread. No country 
reported an endemic situation. The epidemiological sit-
uation for Verona integron-encoded metallo-beta-lac-
tamase (VIM)-producing Enterobacteriaceae remained 
stable with some minor country-specific changes. 
Imipenemase (IMP)-producing Enterobacteriaceae 
remained rare in Europe (Table 3).
Description of the emergence and spread of 
carbapenemase-producing Enterobacteriaceae
The NEs participating in the EuSCAPE provided a 
description of the emergence and spread of CPE in their 
country beyond K. pneumoniae and E. coli isolates col-
lected during the EuSCAPE structured survey.
Denmark, Iceland, Finland, Norway, Sweden and the 
Netherlands
In Denmark, only sporadic occurrence of CPE, mostly 
related to foreign travel, was observed until 2012 
when the situation for CPE changed to sporadic hos-
pital outbreaks with the spread of VIM-4 producing E. 
Epidemiological scale Description Stage
No cases reported No cases reported. 0
Sporadic occurrence Single cases, epidemiological unrelated. 1
Single hospital outbreak Outbreak defined as two or more epidemiologically-associated cases with indistinguishable geno- or phenotype in a single institution. 2a
Sporadic hospital 
outbreaks
Unrelated hospital outbreaks with independent, i.e. epidemiologically-unrelated introduction or 
different strains; no autochthonous inter-institutional transmission reported. 2b
Regional spread More than one epidemiologically-related hospital outbreak confined to hospitals that are part of the same region or health district, suggestive of regional autochthonous inter-institutional transmission. 3
Inter-regional spread Multiple epidemiologically-related outbreaks occurring in different health districts, suggesting inter-regional autochthonous inter-institutional transmission. 4
Endemic situation Most hospitals in a country are repeatedly seeing cases admitted from autochthonous sources. 5
Table 1
Epidemiological stages of carbapenemase-producing Enterobacteriaceae spread [1,3]
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Country
 Epidemiological stage for  the spread of CPE Change in epidemiological situation for 
CPE between 2013 and 20152010a 2013b  2014–2015c 
Albania NA 2a 1 ↓
Austria 0 2b 2b →
Belgium 2b 3 4 ↑
Bosnia and Herzegovina 1 1 0 ↓
Bulgaria 0 2a 2a →
Croatia 1 3 3 →
Cyprus 2a 2a 1 ↓
Czech Republic 1 2b 2b →
Denmark 1 2ad 4 ↑
Estonia 0 2a 1 ↓
Finland 1 2a 2a →
France 3 3 4 ↑
Germany 3 3 3 →
Greece 5 5 5 →
Hungary 3 4 4 →
Iceland 0 0 0 →
Ireland 1 4 3 ↓
Israel 5 4 4 →
Italy 4 5 5 →
Kosovo* NA 2b 0 ↓
Latvia 1 1 1 →
Lithuania 1 1 1 →
Luxembourg NA 1 1 →
Malta 1 5 5 →
Montenegro NA 0 1 ↑
The Netherlands 2a 2b 2a ↓
Norway 2a 2a 1 ↓
Poland 4 3 4 ↑
Portugal 1 1 2b ↑
Romania 1 1 4 ↑
Serbia 1 1 2b ↑
Slovakia NA 2a 4 ↑
Slovenia 0 1 2a ↑
Spain 2b 3 4 ↑
Sweden 2a 2b 2a ↓
The former Yugoslav Republic of Macedonia NA 0 1 ↑
Turkey NA 2a 5 ↑
United Kingdom 2b 3 3 →
CPE: carbapenemase-producing Enterobacteriaceae; NA: not available.
↑: increase in the epidemiological stage between 2013 and 2015; ↓: decrease in the epidemiological stage between 2013 and 2015; →: unchanged epidemiological stage 
between 2013 and 2015.
Grey: countries with no data available.
Dark green: no case reported (Stage 0).
Light green: sporadic occurrence (Stage 1).
Light yellow: single hospital outbreak (Stage 2a).
Dark yellow: sporadic hospital outbreaks (Stage 2b).
Orange: regional spread (Stage 3).
Red: inter-regional spread (Stage 4).
Brown: endemic situation (Stage 5).
a The results were based on data obtained through a Europe-wide consultation during a workshop at the Dutch National Institute for Public Health and the Environment 
(RIVM) on 29–30 April 2010 [3].
b The results were based on data obtained through a self-assessment questionnaire (February 2013) to the national experts who participated in the ‘European survey of 
carbapenemase-producing Enterobacteriaceae (EuSCAPE)’ project [1,2].
c This online survey (March–May 2015).
d Data provided in 2015.
*This designation is without prejudice to positions on status, and is in line with United Nations Security Council resolution 1244/99 and the International Court of Justice 
Opinion on the Kosovo declaration of independence.
Table 2
Comparison of epidemiological stages of carbapenemase-producing Enterobacteriaceae, 38 European countries, 2010–2015
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coli, the identification of NDM-4 producing E. coli and 
an outbreak of NDM-1 producing Citrobacter freundii 
[4,5]. Since 2013, the number of CPE cases in Denmark 
has further increased with multiple epidemiologically-
related hospital outbreaks of OXA-48- and NDM-
producing Enterobacteriaceae in different regions of 
the country [6]. In 2014, most of the CPE cases had no 
history of recent travel aboard. Denmark is now facing 
an inter-regional spread of CPE.
The situation in Iceland has remained unchanged since 
2010 despite active screening. Iceland is one of the few 
countries in Europe that has not reported any case of 
CPE.
In Norway, the occurrence of CPE, KPC-, OXA-48- and 
NDM-producing Enterobacteriaceae, has remained 
sporadic with still a small number of CPE cases (ca 10 
cases per year, including colonisation) since 2013. The 
majority of the identified cases had a link with foreign 
travel.
In Finland, 74 CPE isolates from 66 patients have been 
obtained since 2009, with an increase from five cases 
in 2009 to 18 cases in 2014. About 70% of the patients 
with CPE had a history of foreign travel, mostly to Asia 
or southern Europe. Until 2013, the predominant CPE 
in Finland were OXA-48-producing Enterobacteriaceae 
[7]. In 2013, Finland experienced its largest and first 
outbreak of CPE, involving nine patients without direct 
link to travel abroad. This outbreak of colonisation 
was due to KPC-producing K. pneumoniae ST 512 mak-
ing them the predominant CPE in Finland, although 
still at a very low prevalence [8]. In 2015, eight NDM-
producing Enterobacteriaceae, six KPC-producing 
Enterobacteriaceae and four OXA-48-producing 
Enterobacteriaceae have been isolated so far (data not 
shown).
In Sweden, most identified cases had a history of for-
eign travel. In 2014, there was a slight increase in the 
number of CPE cases due to an outbreak that was only 
detected through identification of a secondary colonised 
case. Until 2013, the predominant CPE in Sweden were 
NDM-producing Enterobacteriaceae closely followed 
by OXA-48-producing Enterobacteriaceae [9]. Since 
2014, OXA-48-producing Enterobacteriaceae became 
predominant over NDM-producing Enterobacteriaceae, 
however both are still at low level.
In the Netherlands, KPC-, OXA-48- and NDM-producing 
Enterobacteriaceae have so far only been responsible 
for single hospital outbreaks, although a recent inter-
institutional outbreak of KPC-producing K. pneumoniae 
occurred following the transfer of a patient from a nurs-
ing home to a hospital [10,11].
Estonia, Latvia and Lithuania
The Baltic countries only recently started to report CPE 
cases [12,13].
In Estonia, the first case of CPE, i.e. German imipen-
emase (GIM)-producing Enterobacter aerogenes, was 
identified in 2015 (personal communication, Paul 
Naaber, 26 June 2015).
In Latvia, only three cases of CPE have been identified 
so far, of which the first two VIM-producing isolates 
were identified during the EuSCAPE structured survey 
(data not shown).
In Lithuania, surveillance of CPE became mandatory 
in 2014. Between 1 January and 31 December 2014, 13 
CPE cases were reported, consisting of two cases of 
OXA-48-producing K. pneumoniae, nine cases of NDM-
producing Enterobacter cloacae, one case of NDM-
producing E. aerogenes and one case of VIM-producing 
E. cloacae.
Ireland and United Kingdom
In Ireland, sporadic occurrence of CPE, i.e. KPC-, VIM- 
and NDM-1-producing Enterobacteriaceae, had been 
reported until 2011, with the majority of cases being 
related to travel abroad [14-16]. In 2011, an outbreak 
of epidemiologically-related KPC-producing K. pneu-
moniae in two hospitals from two different regions 
resulted in epidemiological stage 4 of CPE spread in 
the country [17]. This was concomitant with the first 
hospital outbreak of OXA-48-producing K. pneumo-
niae [18]. Since 2013, although the spread of CPE was 
limited to regional spread in some regions, the over-
all national situation is considered to have worsened 
due to an increase in the overall number of reported 
CPE cases. Furthermore, increasing numbers of hos-
pitals and regions where CPE had not been encoun-
tered before 2013, have since reported sporadic cases 
or outbreaks of CPE. Prior to 2013, KPC-producing 
Enterobacteriaceae were the main type of CPE respon-
sible for hospital outbreaks, but from 2013 onwards, 
OXA-48- and NDM-producing Enterobacteriaceae were 
also responsible for outbreaks.
The United Kingdom (UK), reported the emergence and 
the spread of NDM-1-producing CPE soon after its first 
isolation in 2008 from a patient repatriated to Sweden 
from a hospital in India, and this led to a National 
Resistance Alert 3 notice by the Department of Health 
[19,20]. To date, the UK has reported the largest number 
of NDM-producing CPE cases among European coun-
tries and has seen multiple NDM variants. The number 
of CPE isolates received by the national reference labo-
ratory has increased continuously since 2008. In 2014, 
an increasing number of NDM- or OXA-48-producing 
isolates was reported compared with previous years 
with a marked increase in carbapenemase-producing 
E. coli.
Austria, Czech Republic, Germany, Luxembourg and 
Slovenia
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In Austria, the epidemiological situation worsened 
between 2010 and 2013, but has since remained 
unchanged with a low occurrence of CPE and sporadic 
hospital outbreaks [21-24]. Between 2010 and 2015, the 
most frequently confirmed carbapenemase genes by 
the reference laboratory were blaVIM and blaKPC, but also 
blaOXA-48 and blaNDM were also found in low numbers. In 
April 2015, Austria initiated the Austrian surveillance 
project ‘Carba-Net Austria’ and organised four labora-
tory capacity building workshops on the identification 
of CPE and characterisation of carbapenemases based 
on the EuSCAPE protocols and training curriculum.
In the Czech Republic, the occurrence of CPE was rare 
until 2011 with only sporadic cases, and a total of three 
cases detected between 2009 and 2010. In 2011, how-
ever, the number of CPE increased due to the repatria-
tion of patients from hospitals in Italy and Greece and 
an outbreak following the transfer of a patient from 
Italy [25]. To contain this increase, the national sur-
veillance included CPE isolates from active screening 
samples as part of its surveillance scheme and the 
Ministry of Health issued, in 2012, official national 
guidelines for the control of CPE covering both infected 
and colonised cases. No further increase in the occur-
rence of CPE was observed in 2012 and 2013, and only 
one outbreak restricted to five patients and four spo-
radic cases was reported until mid-2013 [26]. During 
the EuSCAPE survey, the Czech Republic reported only 
two confirmed CPE cases, of which one involved NDM-
1-producing K. pneumoniae from a patient transferred 
from Ukraine [27].
In Germany, there has been an increasing number of CPE 
referred to the German National Reference Laboratory 
for CPE and the German national antibiotic resistance 
surveillance has showed an increase of resistance to 
meropenem in K. pneumoniae from 0.1% in 2010 to 
0.5% in 2014. Both observations possibly indicated 
an increase in the prevalence of CPE in Germany albeit 
on a low level. Several outbreaks with KPC-2-, KPC-
3-, NDM-1- and OXA-48-producing Enterobacteriaceae 
have been documented; notably a protracted KPC-2 
outbreak involving over 100 patients and a polyclonal 
KPC-2 outbreak involving other species besides K. 
pneumoniae [28]. The most prevalent CPE are in order 
of importance OXA-48-, KPC-2-, VIM-1-, NDM-1- and 
KPC-3-producing Enterobacteriaceae. Despite the domi-
nance of OXA-48-producing Enterobacteriaceae, mostly 
KPC-producing K. pneumoniae outbreaks have been 
reported in Germany.
Luxembourg has only experienced sporadic cases of 
VIM-producing CPE [29].
In Slovenia, only sporadic cases of CPE were detected 
until 2013, with a large proportion of the cases being 
related to patient transfers from foreign hospitals [30]. 
The situation changed in October 2014 with the first 
outbreak of both OXA-48- and NDM- producing E. coli 
and K. pneumoniae affecting several wards in a single 
hospital. While one of the first identified patients had 
been transferred from a foreign hospital, other patients 
had no history of travel abroad. Some CPE-positive 
patients belonging to this outbreak were transferred 
to other hospitals across the country, but no further 
spread occurred in these hospitals.
Hungary, Poland, Romania and Slovakia
In Hungary, ca 600 VIM-4-producing Enterobacteriaceae 
isolates – the predominant type of CPE in Hungary 
– have been collected since 2008. The first KPC-2-
producing K. pneumoniae isolates were reported from 
2008 to 2009 during a local outbreak in the north-east-
ern part of Hungary and the index case was a patient 
previously hospitalised in Greece [31]. About 20 KPC-
producing isolates, from sporadic cases and mostly 
associated with medical treatment abroad, have since 
been collected, with an average of 1 to 2 isolates per 
year. These were KPC-producing K. pneumoniae until 
2015 when the first KPC-producing E. coli was iso-
lated. Only two small outbreaks caused by OXA-48-
like-producing K. pneumoniae were reported, in 2012 
and 2014, and both were linked to patient transfers 
from Romania and Ukraine, respectively [32]. In total, 
20 OXA-48-producing Enterobacteriaceae have been 
identified so far in Hungary. Since 2013, only sporadic 
cases of NDM-producing CPE, primarily E. cloacae, 
have been identified, of which some but not all were 
linked to Romania.
In Poland, KPC-producing K. pneumoniae were pre-
dominant between 2008 and 2012 [33,34]. Since 2012, 
the epidemiology of CPE has changed with a decreas-
ing number of KPC-producing K. pneumoniae and an 
increasing number of NDM-1-producing K. pneumoniae. 
The former primarily occurred in the regions that had 
experienced outbreaks of KPC-producing K. pneumo-
niae in 2008–2012. The latter was a consequence of 
a large inter-regional outbreak of NDM-producing K. 
pneumoniae that started at the end of 2012 [35], just 
a few months after the first case of NDM-1-producing 
K. pneumoniae was found in a patient with previous 
travel history to Africa [36].
In Romania, the first confirmed cases of OXA-48- and 
NDM-1-producing Enterobacteriaceae, mostly K. pneu-
moniae, were isolated in 2011 and both OXA-48- and 
NDM-1-producing Enterobacteriaceae were the pre-
dominant CPE in Romania until 2013. During the 
EuSCAPE structured survey, mostly OXA-48- produc-
ing Enterobacteriaceae were found (data not shown) 
[37-39].
Prior to 2013, Slovakia experienced only one small 
local epidemic in two hospitals, following an imported 
case of NDM-1-producing K. pneumoniae [40]. However, 
the situation changed in December 2013 after the iden-
tification of the first case of KPC-2-producing K. pneu-
moniae in a patient who had been hospitalised in 
Greece and the subsequent spread of CPE to more than 
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Country
Epidemiological stage for the spread of CPE by type of carbapenemase
                  KPC                                 OXA48                               VIM                                 NDM                                  IMP                 
2013a 2014–2015b 2013a 2014–2015b 2013a 2014–2015b 2013a 2014–2015b 2013a 2014–2015b
Albania 1 1 2a 0 1 0 0 0 2a 0
Austria 1 2b 1 1 2b 2a 2a 1 0 0
Belgium 3 4 3 4 3 3 1 3 0 0
Bosnia and Herzegovina 0 0 0 0 0 0 0 0 0 0
Bulgaria NA 2a NA 1 2a 1 NA 2a NA 0
Croatia 3 2a 1 3 1 2b 1 2a 1 1
Cyprus NA 1 NA 1 NA 0 NA 0 1 0
Czech Republic 2b 2b 0 1 2a 2b 1 1 0 0
Denmark 1 1 1 1 2ac 0 1 4 0 0
Estonia NA 0 NA 1 NA 0 NA 1 NA 0
Finland 2a 2a 1 1 1 1 1 1 0 1
France 2b 2b 3 4 2b 2b 2a 3 2a 1
Germany 3 2b 2b 3 2b 1 2a 2b 1 1
Greece 5 5 1 1 5 5 0 3 0 0
Hungary 3 1 1 2b 4 4 0 1 0 0
Iceland 0 0 0 0 0 0 0 0 0 0
Ireland 4 3 3 3 2a 1 1 2a 1 1
Israel 4 4 2b 2b 0 1 2a 2b 0 0
Italy 5 5 2b 3 4 4 2b 1 0 0
Kosovo* 2b 0 2b 0 0 0 1 0 0 0
Latvia 1 0 NA 0 NA 1 NA 0 NA 0
Lithuania 0 0 1 1 0 0 0 1 0 0
Luxembourg 1 1 0 1 1 1 0 0 NA 1
Malta 0 c 0 5 5 0c 1 0 c 0 1 1
Montenegro NA 0 NA 0 NA 0 NA 1 NA 0
The Netherlands 2a 2a 2b 2a 1 2a 1 1 1 1
Norway 2a 1 1 1 1 1 1 1 0 1
Poland 3 3 1 1 1 2b 1 4 0 DNK
Portugal 1 2b 0 1 1 1 0 2a 0 0
Romania NA 4 1 4 NA 2a 1 4 NA NA
Serbia NA 1 NA 2b NA 0 NA 2b NA 0
Slovakia NA 4 NA 0 NA 1 2a 1 NA 0
Slovenia 1 1 1 2a 1 1 1 2a 0 0
Spain 2b 3 3 4 3 4 1 2b 2b 1
Sweden 2a 1 1 2a 1 1 2a 1 0 1
The former Yugoslav Republic 
of Macedonia NA 1 NA 0 NA 0 NA 0 NA NA
Turkey 2b 0 1 5 1 2b 1 3 1 1
United Kingdom 3 4d 3 2b 3 2b 2b 2b 1 0
CPE: carbapenemase-producing Enterobacteriaceae; DNK: do not know; IMP: imipenemase; KPC: Klebsiella pneumoniae carbapenemase; NA: not available; NDM: 
New Delhi metallo-beta-lactamase; OXA-48: carbapenem-hydrolysing oxacillinase-48; VIM: Verona integron-encoded metallo-beta-lactamase.
Grey: countries with no data available.
Dark green: no case reported (Stage 0).
Light green: sporadic occurrence (Stage 1).
Light yellow: single hospital outbreak (Stage 2a).
Dark yellow: sporadic hospital outbreaks (Stage 2b).
Orange: regional spread (Stage 3).
Red: inter-regional spread (Stage 4).
Brown: endemic situation (Stage 5).
a The results were based on data obtained through a self-assessment questionnaire (February 2013) to the national experts that participated in the ‘European 
survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE)’ project [1,2].
b This online survey (March–May 2015).
c Data provided in 2015.
d For Scotland, it was not possible to determine the epidemiological stage for each enzyme at the time of the questionnaire however, KPC-producing 
Enterobacteriaceae are sporadic (Stage 1).
*This designation is without prejudice to positions on status, and is in line with United Nations Security Council resolution 1244/99 and the International Court of 
Justice Opinion on the Kosovo declaration of independence.
Table 3
Comparison of epidemiological stages of carbapenemase-producing Enterobacteriaceae by type of carbapenemase, 38 
European countries, 2010–2015
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10 hospitals. The number of patients infected or colo-
nised with KPC-2-producing K. pneumoniae has now 
reached 150. In addition, two small local outbreaks of 
VIM-producing E. cloacae and NDM-producing K. pneu-
moniae were reported up to 2015.
Albania, Bosnia and Herzegovina, Bulgaria, Croatia, 
Kosovo*, Montenegro, Serbia and the former Yugoslav 
Republic of Macedonia
Albania organised two laboratory capacity building 
workshops and urged hospitals not involved in the 
EuSCAPE project to initiate surveillance studies. This 
led to the identification of the first confirmed case of 
KPC-3-producing K. pneumoniae from a patient with 
no recent travel history, but with a previous admission 
in the intensive care unit at the University Hospital in 
Tirana in 2014 [41].
Bosnia and Herzegovina did not report any CPE, but 
NDM-1-producing K. pneumoniae had previously been 
reported in Croatia from a patient transferred from 
Bosnia and Herzegovina [42,43].
In Bulgaria, the occurrence of CPE has increased since 
2012. KPC-2- and VIM-1-producing K. pneumoniae 
were isolated from a hospitalised patient in Varna and 
an outbreak caused by NDM-1-producing E. coli was 
reported from the Military Medical Academy Hospital 
of Sofia [44,45].
In Croatia, the first reported case of CPE was a NDM-
1-producing K. pneumoniae isolated in 2009 in the 
University Hospital Centre of Zagreb from a patient 
repatriated from Bosnia and Herzegovina [42]. In 
February 2011, the first KPC-producing K. pneumoniae 
was isolated from a patient at the same hospital [46]. A 
multicentre study performed from 2011 to 2012 in four 
large hospital centres in Croatia identified a higher 
prevalence of VIM-1-producing Enterobacteriaceae than 
of NDM- and KPC-producing Enterobacteriaceae [47]. 
Since 2014, the epidemiology of CPE in Croatia has 
changed with the rapid spread of OXA-48-producing 
Enterobacteriaceae whereas incidence of KPC isolates 
declined.
Kosovo* is one of the few countries that have not 
reported any cases of CPE isolated from normally ster-
ile body fluids such as blood cultures and cerebrospinal 
fluid (CSF), although NDM-1-producing K. pneumoniae 
were previously reported in Austria, Belgium and in 
Germany from patients being transferred from hospi-
tals in Kosovo* [43,48,49].
In Montenegro, a laboratory capacity building work-
shop was organised and phenotypic methods of detec-
tion of CPE were implemented in the participating 
laboratories, leading to the identification of NDM-1-
producing K. pneumoniae during the EuSCAPE struc-
tured survey (data not shown).
In Serbia, NDM- and OXA-48-producing Enterobacteriaceae, 
as well as NDM- and OXA-48- co-producing 
Enterobacteriaceae have been isolated during the 
EuSCAPE structured survey (data not shown). The latter 
type of CPE was also identified in a patient transferred 
from Serbia to Switzerland in December 2013 [50].
In the former Yugoslav Republic of Macedonia, only KPC-
producing K. pneumoniae have been isolated so far through 
the EuSCAPE structured survey (data not shown).
Belgium, France, Portugal and Spain
In Belgium, the situation of CPE has seriously wors-
ened with a rapid spread of CPE since 2012, i.e. a 
doubling in prevalence and incidence in acute care hos-
pitals between 2012 and 2015 and more than 80% of 
the reported cases being confirmed as autochthonous 
acquisition, i.e. not travel-related. In addition, there has 
been an increase in the number of documented regional 
and inter-regional transmissions of epidemiologically 
related clusters and/or outbreaks, especially for OXA-
48-producing Enterobacteriaceae and to a lesser extent 
for KPC-producing Enterobacteriaceae. There has also 
been an increase in the number of outbreaks with one 
third of the country’s hospitals reporting outbreaks of 
CPE. Another major change in Belgium in 2015 was the 
marked increase, compared with 2013, in the number 
of non-travel-related NDM cases with inter-institution 
regional spread and multiple large difficult-to-control 
outbreaks occurring in several hospitals.
In France, the number of cases and outbreaks of CPE 
has steadily increased since 2009 with the sharpest 
increase during the last quarter of 2014. KPC-producing 
Enterobacteriaceae however, have been declining since 
2012. Most cases were acquired abroad, i.e. through 
hospitalisation or travel. However, there has been an 
increase in the number of autochthonous cases, usu-
ally OXA-48-producing Enterobacteriaceae. In 2014, 
the most frequent CPE are OXA-48-producing K. pneu-
moniae and E. coli, followed by NDM-, VIM- and KPC-
producing Enterobacteriaceae.
In Spain, the situation of CPE has worsened in the last 
few years with an increasing trend in the number of 
CPE cases and a wide geographic spread [51-54]. The 
spread of CPE has currently affected 34/50 Spanish 
provinces, resulting in a potential inter-regional spread 
of CPE [47,49, unpublished data]. The most predomi-
nant CPE are OXA-48- and VIM-producing K. pneumo-
niae [51-53]. In general, the prevalence of KPC- and 
NDM-producing Enterobacteriaceae in Spain is low but 
increasing [51,54]. Recently, an inter-hospital spread 
of NDM-7-producing K. pneumoniae that belonged to 
MLST type 437 was described in Madrid [51]. Although 
not frequent, detection of the polyclonal dissemination 
of OXA-48-producing E. coli is worrying.
In Portugal, only sporadic isolates or single hospital 
cases have been described. The most predominant CPE 
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Country
National 
system for 
surveillance
Officially nominated 
national reference 
laboratory, or expert 
laboratory
National 
recommendation 
or obligation 
for reporting 
(notification) to 
health authorities
National plan for 
containment of 
(or preparedness 
to contain) CPE
National 
recommendation 
or guideline on 
infection control 
measures
Reference or URL for recommendation or 
guideline on infection control measures
Albania -a, b -a -a
Austria ●c ● ●d ●
http://www.analyse.eu/content/inhalte/
nationales_referenzzentrum/station%C3%A4re_
patienten_mit_auslandsanamnese/index.html 
Belgium ●e ● ●f ● ●
http://www.health.belgium.be/internet2Prd/
groups/public/@public/@shc/documents/
ie2divers/19074512.pdf  
http://www.sante.belgique.be/internet2Prd/
groups/public/@public/@shc/documents/
ie2divers/19074512_nl.pdf 
Bosnia and 
Herzegovina -
a, b -a -a
Bulgaria ● ● ● -a ●
Croatia ●e ● ●f ● ●
Cyprus -e,g ●h
Czech Republic ●e ● ●f ● ●
http://www.mzcr.cz/Legislativa/dokumenty/
vestnik-c8/2012_6865_2510_11.html  
http://www.szu.cz/
narodni-referencni-laborator-pro-antibiotika 
Denmark ●c ●
Estonia -g ●d
Finland ●e ● ●f ● http://urn.fi/URN:ISBN:978-952-302-260-7 
France ●e ● ●f ● ● http://www.sante.gouv.fr/fichiers/bo/2014/14-02/ste_20140002_0000_0064.pdf 
Germany ●c ● -a ● http://edoc.rki.de/documents/rki_ab/resuFm0GFF7o/PDF/21obND4dxM.pdf 
Greece ●e ●h ●f ● ●
http://www.keelpno.gr/el-gr/
νοσήματαθέματαυγείας/πολυανθεκτικάπαθογό
ναστανοσοκομεία.aspx 
Hungary ●e ●h ●f -a ● http://www.oek.hu/oek.web?nid=1067&pid=1&to=&lang=hun 
Iceland ●e ● ●f ● ●
Ireland ●e ● ●d ●
http://www.hpsc.ie/hpsc/A-Z/
MicrobiologyAntimicrobialResistance/
InfectionControlandHAI/Guidelines/
File,12922,en.pdf 
Israel ●e ● ●f ● ●
Italy ●c ●h ●d -a ●
http://www.trovanorme.salute.gov.it/renderNor
msanPdf?anno=0&codLeg=45499&parte=1%20
&serie= 
Kosovo* -a, b ●h -a
Latvia ●e ●h ●f -a
Lithuania ●e ●
Luxembourg ●c ●h ●d ●
Malta ●e ●h -a ●
Montenegro -a, b -a ●f
The 
Netherlands ●
c ●h -a ● http://www.rivm.nl/dsresource?objectid=rivmp:46410&type=org&disposition=inline&ns_nc=1 
Table 4 A
National capacity for surveillance and containment of carbapenemase-producing Enterobacteriaceae, 38 European countries, 
May 2015
CPE: carbapenamase-resistant Enterobacteriaceae.
In the table cells, a dot signifies ‘in place’ and the absence of dot signifies ‘absent’. Black colour indicates that the system or document was already in place in 2013. Blue 
colour indicates a change reported in 2015, as compared with 2013.
a In preparation.
b No national system for surveillance, but country reports carbapenem-resistant invasive isolates (Klebsiella pneumoniae and Escherichia coli) to the Central Asian and 
Eastern European Surveillance on Antimicrobial Resistance (CAESAR).
c Voluntary participation of the laboratories.
d Voluntary notification to health authorities.
e Mandatory participation of the laboratories (for the United Kingdom, only mandatory for Scotland).
f Mandatory notification to health authorities (for the United Kingdom, only mandatory for Scotland).
g No national system for surveillance, but country reports carbapenem-resistant invasive isolates (K. pneumoniae and E. coli) to the European Antimicrobial Resistance 
Surveillance Network (EARS-Net).
h An expert laboratory fulfils a similar role to that of a national reference laboratory.
*This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the Internal Court of Justice 
Opinion on the Kosovo declaration of independence.
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were KPC-producing Enterobacteriaceae, but OXA-48-
producing Enterobacteriaceae have also been recently 
reported [55,56].
Cyprus, Greece, Israel, Italy, Malta and Turkey
During the EuSCAPE structured survey, Cyprus col-
lected only three CPE isolates (data not shown). In 
line with this, the latest data from the European 
Antimicrobial Resistance Surveillance Network (EARS-
Net) showed a decreasing trend in the percentage of 
carbapenem-resistant isolates among invasive, i.e. 
blood and cerebrospinal fluid (CSF), K. pneumoniae 
isolates from 15.7% to 5% during 2011 to 2014 [12,57].
Since the early 2000s, Greece has been first facing a 
nationwide epidemic of polyclonal VIM-producing K. 
pneumoniae followed by a nation-wide occurrence of 
Country
National 
system for 
surveillance
Officially nominated 
national reference 
laboratory, or expert 
laboratory
National 
recommendation 
or obligation 
for reporting 
(notification) to 
health authorities
National plan for 
containment of 
(or preparedness 
to contain) CPE
National 
recommendation 
or guideline on 
infection control 
measures
Reference or URL for recommendation or 
guideline on infection control measures
Norway ●e ● ●f -a ●
http://www.fhi.no/dokumenter/96331178b9.pdf  
http://www.fhi.no/eway/default.aspx?pid=2
39&trg=List_6212&Main_6157=6263:0:25,6
493&MainContent_6263=6464:0:25,6513&L
ist_6212=6453:0:25,6499:1:0:0:::0:0 
Poland ●e ● ●f ● http://www.antybiotyki.edu.pl/pdf/kpc-20120713.pdf 
Portugal ●e ● ●f ● -a
Romania ●c ●h -a http://www.srm.ro 
Serbia ●c ●
Slovakia ●e ●h ●f ● ● http://www.ruvztn.sk/OU%20MZ%20SR.pdf 
Slovenia -a, g ●h -a ●
http://www.mz.gov.si/fileadmin/mz.gov.
si/pageuploads/mz_dokumenti/delovna_
podrocja/zdravstveno_varstvo/zdravstveno_
varstvo_v_posebnih/NAKOBO_oktober_2010/
PRIPOROCILA_ESBL_26.10.10.pdf 
Spain ●c ●h ●d -a ●
http://www.aemps.gob.es/publicaciones/
publica/docs/plan-estrategico-antibioticos.pdf  
http://www.madrid.org/cs/Satellite?blobcol=u
rldata&blobheader=application%2Fpdf&blobh
eadername1=Content-disposition&blobheader
name2=cadena&blobheadervalue1=filename%
3DPLAN+PREVENCI%C3%93N+Y+CONTROL+EPC
+CM_v1_sept+2013.pdf&blobheadervalue2=lan
guage%3Des%26site%3DPortalSalud&blobkey
=id&blobtable=MungoBlobs&blobwhere=13528
38664739&ssbinary=true  
http://safh.org/wp-content/uploads/2014/10/
Programa-para-el-control-de-las-EPC_SSPA.pdf 
Sweden ●e ● ●f ● ●
http://www.folkhalsomyndigheten.se/page-
files/17838/ESBL-producerande%20tarmbakterier.
pdf 
The former 
Yugoslav 
Republic of 
Macedonia
●e ●h ●f
Turkey ● ●h ●d
United 
Kingdom ●
c, e ● ●d, f ● ●
https://www.gov.uk/government/publications/
carbapenemase-producing-enterobacteriaceae-
early-detection-management-and-control-
toolkit-for-acute-trusts  
http://www.documents.hps.scot.nhs.uk/hai/
amr/cpe-guidance.pdf 
CPE: carbapenamase-resistant Enterobacteriaceae.
In the table cells, a dot signifies ‘in place’ and the absence of dot signifies ‘absent’. Black colour indicates that the system or document was already in place in 2013. Blue 
colour indicates a change reported in 2015, as compared with 2013.
a In preparation.
b No national system for surveillance, but country reports carbapenem-resistant invasive isolates (Klebsiella pneumoniae and Escherichia coli) to the Central Asian and 
Eastern European Surveillance on Antimicrobial Resistance (CAESAR).
c Voluntary participation of the laboratories.
d Voluntary notification to health authorities.
e Mandatory participation of the laboratories (for the United Kingdom, only mandatory for Scotland).
f Mandatory notification to health authorities (for the United Kingdom, only mandatory for Scotland).
g No national system for surveillance, but country reports carbapenem-resistant invasive isolates (K. pneumoniae and E. coli) to the European Antimicrobial Resistance 
Surveillance Network (EARS-Net).
h An expert laboratory fulfils a similar role to that of a national reference laboratory.
*This designation is without prejudice to positions on status, and is in line with United Nations Security Council Resolution 1244/99 and the Internal Court of Justice 
Opinion on the Kosovo declaration of independence.
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mainly monoclonal KPC-2-producing K. pneumoniae. 
The first NDM-1-producing K. pneumoniae isolate was 
reported in 2012 in a patient repatriated from Albania 
[58,59]. Since 2012, NDM-producing Enterobacteriaceae 
have been isolated from patients in 15 Greek hospi-
tals and several clonal outbreaks of NDM-1-producing 
Enterobacteriaceae have been reported with only a 
few cases in each outbreak, therefore of much smaller 
magnitude than earlier and concurrent outbreaks with 
KPC-producing Enterobacteriaceae. OXA-48-producing 
Enterobacteriaceae are still rarely isolated. According 
to EARS-Net data, Greece had the highest percentage 
of carbapenem-resistant isolates among invasive K. 
pneumoniae in Europe in 2014, with more than 62% 
of K. pneumoniae invasive isolates being carbapenem-
resistant, but with a decreasing trend from 68.2% in 
2011 to 62.3% in 2014.
In Israel, CPE were rarely detected until 2006 when the 
situation changed dramatically, with the nationwide 
spread of KPC-producing K. pneumoniae. This led the 
Ministry of Health to initiate a nationwide intervention 
plan aiming to contain the spread [60]. The situation 
of CPE is now stable and the spread of CPE has been 
contained for several years, but CPE are not eradicated. 
Recently, several reports have indicated that NDM- and 
OXA-48-producing Enterobacteriaceae, are now present 
in Israel [61-63].
In Italy, it was not until 2010 that CPE became a major 
issue when KPC-producing K. pneumoniae became 
endemic, due to a rapid countrywide diffusion mostly 
caused by strains of clonal complex 258 [64]. This 
increase in percentages of carbapenem resistance in 
invasive K. pneumoniae isolates has been documented 
by EARS-Net since 2010 and the latest data from EARS-
Net reported that 32.9% of K. pneumoniae invasive 
isolates were carbapenem-resistant [12]. NDM-1- and 
OXA-48-producing Enterobacteriaceae have been 
reported but their dissemination was still limited and 
cases were mostly acquired abroad [65-67]. In an effort 
to control and prevent the further spread of CPE, the 
Ministry of Health issued a circular letter in 2013 asking 
the public health offices across the country to report 
all cases of bacteraemia caused by CPE to the regional 
and national authorities. Although there is still under-
reporting of CPE, more than 2,000 CPE bacteraemia 
cases have been reported since publication of the cir-
cular letter. One worrisome recent development is the 
rapid and country-wide dissemination of resistance to 
colistin in KPC-producing K. pneumoniae [68] and the 
presence of pandrug-resistant (PDR) strains (data not 
shown).
In Malta, dissemination of OXA-48-producing 
Enterobacteriaceae had changed the country’s epide-
miological level from rare sporadic occurrence before 
2010 to an endemic situation by 2013 [1,2]. It is thought 
that the influx of injured Libyan war victims to the inten-
sive treatment unit of the country’s only tertiary care 
hospital in 2011 contributed to the first outbreak and 
spread of OXA-48-producing Enterobacteriaceae in the 
country [69]. Despite initial control of the outbreak, 
the situation rapidly became endemic in this hospi-
tal and OXA-48-producing Enterobacteriaceae spread 
to other health and residential care entities on the 
Maltese islands. Until 2014, no KPC- or NDM-producing 
Enterobacteriaceae were reported while during the 
same period more than 400 new cases of OXA-48-
producing Enterobacteriaceae were identified. Since 
then, the number of new cases of OXA-48-producing 
Enterobacteriaceae has continued to increase. In addi-
tion, sporadic cases of VIM- and NDM- producing 
Enterobacteriaceae were recently identified, mainly 
acquired outside the country. EARS-Net data for Malta 
showed an increase in the percentage of invasive car-
bapenem-resistant K. pneumoniae, OXA-48 –producing 
K. pneumoniae, from 3.8% to 9.9% during the period 
2011 to 2014 [12].
In Turkey, OXA-48-producing Enterobacteriaceae 
are endemic, and since 2013, an increasing num-
ber of reports have demonstrated the emergence of 
other types of CPE (e.g. NDM-1- and KPC-producing 
Enterobacteriaceae) [70]. This was confirmed by the 
results of the EuSCAPE structured survey (data not 
shown). Reports of NDM-1-producing Enterobacteriaceae 
cases have been increasing, especially in hospi-
tals from cities close to the Syrian border. The latter 
development is in accordance with recent reports on 
both autochthonous and imported NDM-1-producing 
Enterobacteriaceae cases in Turkish hospitals [71,72]. 
In 2015, the first K. pneumoniae co-producing OXA-48 
and NDM-1 was isolated from a patient treated in the 
hospital of Sanliurfa, a city close to the border with 
Syria [73].
National capacity for surveillance and containment of 
carbapenamase-resistant Enterobacteriaceae
Table 4 summarises the existing surveillance and refer-
ence laboratory systems in place as well as the avail-
able national guidance documents for the containment 
of CPE in the participating countries at the time of the 
survey.
Surveillance of carbapenamase-resistant Enterobacteriaceae
Twenty-five EU Member States, Norway and Iceland 
had a dedicated national system for surveillance of 
CPE. Three EU Member States did not have a dedicated 
national surveillance system but reported carbapenem-
resistant K. pneumoniae and E. coli from blood and CSF 
to EARS‐Net. Slovenia, one of these, reported that at 
the time it was developing a dedicated national system 
for surveillance of CPE for implementation by the end 
of 2015. The Netherlands, which has a system in place, 
reported that enhanced surveillance of CPE will take 
place from 2016 onwards. In order to increase labora-
tory participation and coverage as well as to improve 
data quality, the enhanced surveillance should fur-
ther optimise diagnostic testing and integrate clinical, 
molecular and epidemiological data for all CPE cases to 
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determine relevant risk factors to target interventions 
and control potential spread.
All EU enlargement countries and Israel reported par-
ticipating in the Central Asian and Eastern European 
Surveillance on Antimicrobial Resistance (CAESAR) 
network, a joint initiative of the European Society 
of Clinical Microbiology and Infectious Diseases 
(ESCMID), the Dutch National Institute for Public Health 
and the Environment (RIVM) and the World Health 
Organization Regional Office for Europe (WHO/Europe). 
However, only Serbia, the former Yugoslav Republic of 
Macedonia and Turkey have so far reported data to 
CAESAR using the EARS-Net methodology [74]. Israel, 
Serbia, the former Yugoslav Republic of Macedonia and 
Turkey had dedicated national systems for the surveil-
lance of CPE, while Albania, Bosnia and Herzegovina, 
Kosovo* and Montenegro were developing their sur-
veillance system to be able to report data to CAESAR 
by 2015 or2016.
Of 31 countries with a dedicated national surveillance 
system for CPE, 20 countries reported that surveil-
lance of CPE was mandatory for all laboratories, nine 
countries reported that surveillance of CPE was vol-
untary and two countries did not specify. In Romania 
and Serbia, surveillance was voluntary and in form of 
a sentinel system of individual laboratories. In Ireland, 
laboratory participation was only mandatory for inva-
sive disease caused by CPE, i.e. isolation from blood 
and CSF, but remained voluntary for CPE isolated from 
other body sites (Table 4).
Laboratory capacity for carbapenamase-resistant 
Enterobacteriaceae
Thirty-four countries reported having an officially 
nominated national reference laboratory for CPE or 
a national expert laboratory that fulfilled a similar 
role. Both Albania and Montenegro reported that the 
national reference laboratory was in development for 
implementation by 2015–2016 (Table 4).
Notification to health authorities for carbapenamase-
resistant Enterobacteriaceae
Twenty-six countries reported having a national rec-
ommendation for reporting to health authorities CPE-
positive patients identified by diagnostic laboratories. 
In most countries there is mandatory notification for all 
private and hospital laboratories and for all infections; 
only seven countries notified CPE cases on a voluntary 
basis. In two of the latter, notification of CPE cases was 
voluntary but notification of CPE outbreaks was man-
datory. Slovenia and Germany reported that national 
recommendations or obligations for reporting were 
going to be implemented by the end of 2015, and for 
Bosnia and Herzegovina this is planned by 2016–2017 
(Table 4).
National plan for containment of and infection 
control measures for carbapenamase-resistant 
Enterobacteriaceae
Eleven countries had implemented a national plan for 
the containment or for preparedness to contain CPE, 
and another nine countries were developing national 
containment plans. Spain had no national but regional 
specific plans.
Twenty-four countries reported having national rec-
ommendations or guidelines for infection prevention 
and control measures to be applied for patients con-
firmed as being infected or colonised with CPE: for six 
countries this applied to single CPE cases, for 15 to 
single CPE cases and outbreaks, for Greece this only 
applied to outbreaks and two countries did not spec-
ify the scope of their recommendations. Twelve of the 
national recommendations or guidelines were specific 
guidance documents for prevention and control of CPE, 
while nine were included as part of a general guidance 
document for multidrug-resistant organisms (MDROs) 
that specifically referred to CPE and three included a 
general guidance document for MDROs not specifically 
referring to prevention and control of CPE. Kosovo* 
and Portugal indicated that such recommendations or 
guidelines are in preparation for implementation by the 
end of 2015.
The most cited measures in such national recom-
mendations or guidelines were isolation e.g. in sin-
gle rooms, of suspected/colonised/infected patients 
and increased hand hygiene compliance (21 countries 
each), followed by active screening for early detec-
tion at admission of patients having been hospitalised 
abroad, implementation of contact precautions, for 
visitors and medical staff, and implementation of envi-
ronmental hygiene procedures e.g. decontamination of 
equipment and disposal of waste (20 countries each), 
active screening for early detection of transferred 
patients from other wards/hospitals at admission (19 
countries), cohorting of suspected/colonised/infected 
patients (18 countries), active screening for early detec-
tion of colonised patients at admission (16 countries), 
dedicated infection control teams (14 countries), sepa-
rate cohort nursing care e.g. nurses, doctors (13 coun-
tries), specialised training for nursing staff in infection 
control (12 countries), implementation of an antibiotic 
stewardship programme (11 countries), and audit and 
feedback to local, regional or national health authori-
ties (10 countries).
Discussion
In 2013, at the beginning of the EuSCAPE project, 
knowledge about the spread and occurrence of CPE 
was heterogeneous among European countries [1]. 
Moreover, some NEs expressed concerns that under-
detection affected the epidemiological self-assessment 
of their country. Following EuSCAPE activities including 
a capacity building workshop and an EQA exercise to 
improve the detection of CPE and the identification of 
14 www.eurosurveillance.org
the different carbapenemases circulating in Europe, the 
results of this follow-up survey provide evidence that 
the activities contributed to the desired improvement 
and increased awareness and knowledge of the epide-
miology of CPE in many participating countries. After 
participation in the EuSCAPE project, all countries were 
able to self-assess their current situation, whereas only 
26 countries could do so in 2013. In addition, all partic-
ipating countries were able to rate the occurrence and 
spread of CPE according to the type of carbapenemase, 
while such data were only partially or not available in 
several European countries in 2013 [1,2].
In 2015, 13/38 countries reported inter-regional spread 
of or an endemic situation for CPE, compared with 6/38 
countries in 2013. In addition, the survey documented 
the more frequent reporting of OXA-48- and NDM-
producing Enterobacteriaceae compared with 2013. 
For OXA-48-producing Enterobacteriaceae, four coun-
tries had reported regional spread and only one coun-
try had reported an endemic situation in 2013, while 
in 2015, three countries reported regional spread, 
four reported inter-regional spread and two reported 
an endemic situation. Similarly for NDM-producing 
Enterobacteriaceae, only Italy and the UK had reported 
sporadic hospital outbreaks in 2013, while in 2015 six 
countries reported sporadic hospital outbreaks and 
seven countries reported regional and inter-regional 
spread. For the countries that were uncertain about 
their epidemiological stage in the 2013 survey, the 
results of this survey reflect an improved ability to 
detect CPE and identify the different carbapenemases. 
For the other countries, the changes in epidemiological 
stages observed between 2013 and 2015 likely reflect 
an increasing spread of CPE, as confirmed by the NEs. 
At the same time, increased awareness of CPE spread 
and surveillance might also contribute to increased 
detection and reporting of more advanced epidemio-
logical stages. Indeed, countries with strict screening 
policies are more likely to report such advanced epide-
miological stages.
The establishment of a surveillance system for CPE, 
based on the notification of CPE cases to health 
authorities, supported by reference laboratory confir-
mation and identification as well as, molecular typing 
services are the cornerstones of efficient monitoring 
and controlling of the spread of CPE. Many countries 
have developed dedicated surveillance systems and 
designated reference laboratories over the last two 
years, as well as implemented mandatory laboratory 
participation in CPE surveillance, or mandatory report-
ing of all cases of infections. However, despite the 
increased awareness and the worsening of the epide-
miological situation in 2015, only 25 of the 38 countries 
that participated in the EuSCAPE project had enacted 
mandatory notification of CPE cases to health authori-
ties. Active reporting of CPE cases should be encour-
aged by making all clinical cases notifiable to public 
health authorities.
Twenty countries had either implemented a national or 
regional plan for the containment of, or preparedness 
to contain, CPE or were developing national contain-
ment plans. However, national guidance documents on 
infection prevention and control of CPE were not avail-
able in 14 countries. In an effort to support health-
care professionals, hospital administrators and public 
health professionals, ECDC published an online direc-
tory of guidance documents on prevention and control 
of carbapenem-resistant Enterobacteriaceae by EU/EEA 
Member States, ECDC, international and national agen-
cies and professional societies [75,76].
A major impending threat to public health as a conse-
quence of the expanding CPE epidemic in Europe is the 
emergence of PDR strains causing untreatable infec-
tions. Polymyxins, and particularly colistin, represent 
a last-line option for the treatment of patients infected 
with CPE. The latest data available from the European 
Surveillance of Antimicrobial Consumption Network 
(ESAC-Net) show that consumption of polymyxins, 
mainly colistin, in Europe, almost doubled between 
2009 and 2013 [77]. In parallel to this increasing colis-
tin consumption, colistin resistance is increasing in 
carbapenem-resistant Enterobacteriaceae [68,77,78]. In 
Italy, 43% of KPC-producing K. pneumoniae isolates col-
lected during the EuSCAPE structured survey in 2013 to 
2014 [68] and 13% of carbapenem-resistant K. pneumo-
niae isolates from blood cultures reported to EARS-Net 
in 2014 were resistant to colistin [12]. Approximately 
20% of carbapenem-resistant K. pneumoniae isolates 
from blood cultures reported to EARS-Net in 2014 were 
resistant to colistin in Romania and Greece [12]. In 
February 2015, a Greek hospital reported an outbreak 
of PDR Enterobacteriaceae, via the acquisition of blaVIM 
by the naturally colistin- resistant Providencia stuar-
tii, in an intensive care unit occurring in September to 
November 2011 [79].
The accumulation of other resistance markers in CPE 
strains in addition to colistin resistance makes it likely 
that Europe will soon witness an increasing number of 
outbreaks of extensively drug-resistant (XDR) or PDR 
Enterobacteriaceae [57], for which few or even no treat-
ment options are available. The Unites States Food and 
Drug Administration (FDA) recently approved the use 
of a combination of a well-established β-lactam anti-
biotic, ceftazidime, with a novel β-lactamase inhibitor, 
avibactam, for treatment of serious infections caused 
by resistant Gram-negative pathogens. Ceftazidime-
avibactam is active against OXA-48- and KPC-producing 
Enterobacteriaceae but not NDM- or VIM-producing 
Enterobacteriaceae and would offer a partial solution 
to treat infections due to XDR or PDR Gram-negative 
bacteria.
In conclusion, the EuSCAPE project and this follow-
up survey confirm the urgent need for a coordinated 
European effort for surveillance, control and preven-
tion of CPE in Europe. The project contributed to the 
improvement of the capacity and ability to detect CPE 
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in Europe by creating a European network of national 
reference/expert laboratories able to provide informa-
tion for monitoring incidence and spread of carbapen-
emases in the 38 participating countries. Furthermore, 
results presented here show the need to develop an 
EU-wide system for public health surveillance of high-
risk CPE clones and mobile genetic vectors of epi-
demic carbapenemases across the healthcare systems 
in Europe for informing risk assessment and control 
programmes.
*This designation is without prejudice to positions 
on status, and is in line with United Nations Security 
Council Resolution 1244/99 and the International 
Court of Justice Opinion on the Kosovo declaration of 
independence.
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